Prestige Consumer Healthcare Inc. (NYSE:PBH) to Post Q3 2026 Earnings of $1.20 Per Share, Zacks Research Forecasts

Prestige Consumer Healthcare Inc. (NYSE:PBH) – Zacks Research increased their Q3 2026 earnings per share estimates for Prestige Consumer Healthcare in a research note issued to investors on Thursday, May 2nd. Zacks Research analyst R. Department now anticipates that the company will post earnings per share of $1.20 for the quarter, up from their prior forecast of $1.19. The consensus estimate for Prestige Consumer Healthcare’s current full-year earnings is $4.33 per share. Zacks Research also issued estimates for Prestige Consumer Healthcare’s FY2026 earnings at $4.76 EPS.

Several other brokerages also recently weighed in on PBH. StockNews.com raised Prestige Consumer Healthcare from a “hold” rating to a “buy” rating in a report on Saturday, February 10th. TheStreet raised Prestige Consumer Healthcare from a “c+” rating to a “b-” rating in a report on Monday, February 12th. One equities research analyst has rated the stock with a hold rating and two have issued a buy rating to the company’s stock. According to data from MarketBeat.com, Prestige Consumer Healthcare currently has a consensus rating of “Moderate Buy” and a consensus price target of $110.00.

Prestige Consumer Healthcare Price Performance

Shares of NYSE PBH opened at $70.00 on Monday. The company has a debt-to-equity ratio of 0.75, a quick ratio of 1.92 and a current ratio of 3.09. The company has a market cap of $3.48 billion, a PE ratio of -42.68, a P/E/G ratio of 1.90 and a beta of 0.53. The business has a 50-day simple moving average of $71.12 and a two-hundred day simple moving average of $64.66. Prestige Consumer Healthcare has a fifty-two week low of $55.96 and a fifty-two week high of $75.31.

Prestige Consumer Healthcare (NYSE:PBH) last issued its quarterly earnings results on Thursday, February 8th. The company reported $1.06 earnings per share for the quarter, topping the consensus estimate of $1.04 by $0.02. The business had revenue of $282.74 million during the quarter, compared to the consensus estimate of $280.25 million. Prestige Consumer Healthcare had a positive return on equity of 14.09% and a negative net margin of 7.11%. The company’s quarterly revenue was up 2.6% on a year-over-year basis. During the same quarter last year, the company earned $1.04 earnings per share.

Insider Transactions at Prestige Consumer Healthcare

In other news, SVP Mary Beth Fritz sold 5,336 shares of the firm’s stock in a transaction dated Thursday, February 8th. The stock was sold at an average price of $69.00, for a total value of $368,184.00. Following the completion of the transaction, the senior vice president now directly owns 15,934 shares in the company, valued at $1,099,446. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Company insiders own 1.60% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the company. GAMMA Investing LLC purchased a new position in Prestige Consumer Healthcare during the fourth quarter valued at approximately $25,000. Pacer Advisors Inc. raised its position in Prestige Consumer Healthcare by 85.7% during the fourth quarter. Pacer Advisors Inc. now owns 442 shares of the company’s stock valued at $27,000 after acquiring an additional 204 shares in the last quarter. Provence Wealth Management Group purchased a new position in Prestige Consumer Healthcare during the third quarter valued at approximately $26,000. Principal Securities Inc. purchased a new position in Prestige Consumer Healthcare during the fourth quarter valued at approximately $29,000. Finally, ORG Partners LLC purchased a new position in Prestige Consumer Healthcare during the fourth quarter valued at approximately $36,000. 99.95% of the stock is currently owned by hedge funds and other institutional investors.

Prestige Consumer Healthcare Company Profile

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.